¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÁ¾¾ç³»°úÇÐȸ Liver Cancer Symposium 2023 : 2023-11-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑÁ¾¾ç³»°úÇÐȸ Liver Cancer Symposium 2023 : 2023-11-11
±³À°ÀÏÀÚ : 2023-11-11
±³À°Àå¼Ò : ÀÎÅÍÄÁƼ³ÙÅ» ÄÚ¿¢½º ´ÙÀ̾ƸóµåȦ

±³À°ÁÖÁ¦ : Liver Cancer Symposium 2023

ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ±è¿¹Áö
¿¬¶ôó : 02-735-2857  

À̸ÞÀÏ : meetings@ksmo.or.kr

±³À°Á¾·ù : ³»°ú

Âü¼®¿¹»óÀÎ : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 25ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í "Á¤È¸¿ø 30000¿ø / ÁØȸ¿ø 10000¿ø 

ºñȸ¿ø 50000¿ø"  


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 09:00~09:05 Opening À̸í¾Æ(¼­¿ï¼º¸ðº´¿ø)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 09:05~09:30 Pemigatinib-related translational research, translational learnings regarding the treatment of cancers with FGFR alterations Aidan Gilmartin(Incyte Corporation)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 09:30~09:50 The Role of Radiation Therapy for intrahepatic lesions ¹ÚÈñö(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 09:50~10:10 TARE vs TACE ±è°Ç¿µ(ºÐ´ç¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 10:10~10:30 Expanding the Role of Surgical Resection and Transplantation in Intermediate-Stage HCC ÀÌÇØ¿ø(ºÐ´ç¼­¿ï´ëÇб³º´¿ø)

Åä·Ð 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 10:30~10:50 Case Discussion õÀç°æ(¾Æ»êº´¿ø)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 11:00~11:20 Adjuvant Therapy in HCC? ±èÈ«½Ä(ÃæºÏ´ëÇб³)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 11:20~11:40 Systemic Therapy in Intermediate-Stage HCC: A Paradigm Shift? ±èÅ¿ë(¼­¿ï´ëº´¿ø)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 11:40~12:00 Optimal First-Line Therapy for HCC ±èÁÖ¿ø(°í·Á´ëÇб³¾È¾Ïº´¿ø)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 12:00~12:20 Potential Biomarkers for immunotherapy ÀüÈ«Àç(ºÐ´çÂ÷º´¿ø)

Åä·Ð 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 12:20~12:30 Discussion ( )

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 12:30~13:30 Optimal treatment selection for 1L uHCC patients ; Focused on the potential candidates for TKIs? È«Á¤¿ë(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 13:30~13:50 Pathological and Molecular Features of Intrahepatic Cholangiocarcinoma ±èÇý·É(¼­¿ï´ëÇб³º´¿ø)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 13:50~14:10 Surgical Management of Intrahepatic Cholangiocarcinoma: A Comparison with HCC ÇÑ´ëÈÆ(¼¼ºê¶õ½ºº´¿ø)

±³À°½Ã°£ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 14:10~14:30 Systemic Therapy for Intrahepatic Cholangiocarcinoma: Current and Future Perspectives ÃÖÇýÁø(¼¼ºê¶õ½ºº´¿ø)

Åä·Ð 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 14:30~14:40 Discussion ( )

±âŸ 11¿ù 11ÀÏ ´ÙÀ̾ƸóµåȦ 14:40~14:45 Closing ( )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÁ¾¾ç³»°úÇÐȸ Liver Cancer Symposium 2023 : 2023-11-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Á¦12ȸ ´ëÇÑÀ忬±¸ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ ¿¬¼ö°­Á : 2023-11-11
´ÙÀ½±Û PRS KOREA 2023 ´ëÇѼºÇü¿Ü°úÇÐȸ Á¦81Â÷ ±¹Á¦Çмú´ëȸ(1ÀÏÂ÷) : 2023-11-10
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
326 ¼­¿ï Á¦ 4ȸ ´ëÇÑÇǺÎÁø±ÕÇÐȸ ¿¬¼ö±³À° : 2018-08-31 0 514 2018-08-08
325 ÀüºÏ Á¦20ȸ ¿µÈ£³²³»ºÐºñ´ë»çÇÐȸ Çмú´ëȸ : 2018-08-31 0 1,189 2018-08-08
324 ´ë±¸ ´ë±¸°æºÏ°³¿ø³»°úÀÇ»çȸ ¿¬¼ö°­Á : 2018-08-28 0 1,017 2018-08-08
323 ¼­¿ï ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ºÒ¸éÁõ ÀÎÁöÇൿġ·á : 2018-08-26 0 1,646 2018-08-08
322 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø Á¦ 23ȸ °¡Å縯 ¾È°ú Çмú ½ÉÆ÷Áö¾ö : 2018-08-26 0 1,625 2018-08-08
321 ¼­¿ï ´ëÇÑ°³¿øÀÇÇùÀÇȸ 2018³âµµ Á¦2Â÷ ȸ¿ø¿¬¼ö±³À° : 2018-08-26 0 4,052 2018-08-08
320 ´ëÀü ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ Á¦10ȸ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­±³À° (part3, 2ÀÏÂ÷) : 2018-08-26 0 912 2018-08-08
319 ¼­¿ï °í·Á´ëÇб³¾È»êº´¿ø Á¦14ȸ °í·ÁÀÇ´ë ÇǺΰúÇб³½Ç ½ÉÆ÷Áö¾ö ¹× ¿öÅ©¼ó : 2018-08-26 0 708 2018-08-08
318 ´ë±¸ 2018³â Á¦1ȸ ´ëÇÑ°¨¿°ÇÐȸ ¿µ³²Áöȸ ¿¬¼ö°­Á : 2018-08-25 0 879 2018-08-08
317 ´ëÀü 2018 ´ëÇÑ¿Ü°ú¼ú±â¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö ¹× Æ©ÅÍ ¿öÅ©¼ó : 2018-08-25 0 418 2018-08-08
316 Ãæ³² Àü³²´ëÇб³º´¿ø 2018 Á¦ 20Â÷ ºû°íÀ»½½°üÀý¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2018-08-25 0 731 2018-08-08
315 ´ëÀü ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ Á¦10ȸ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­±³À° (part3, 1ÀÏÂ÷) : 2018-08-25 0 762 2018-08-08
314 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø 2018 Yunsei Nuclear Medicien Review course : 2018-08-25 0 532 2018-08-08
313 ¼­¿ï °­µ¿°æÈñ´ëÇб³º´¿ø 2018 °­µ¿°æÈñ´ëÇб³ Á¤Çü¿Ü°ú ½ÉÆ÷Áö¿ò : 2018-08-25 0 1,762 2018-08-08
312 ±¤ÁÖ Àü³²´ëÇб³º´¿ø 2018³â Á¦4ȸ ½Å°æ¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-08-25 0 718 2018-08-08
1391 | 1392 | 1393 | 1394 | 1395 | 1396 | 1397 | 1398 | 1399 | 1400
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷